Dr. Pablo Arnoletti is an award-winning surgical oncologist who directs his extensive clinical expertise and advanced surgical skills to the evaluation and treatment of patients with pancreatic, liver, bile duct, stomach and bowel cancers. He also specializes in treating patients with adrenal tumors, soft tissue sarcomas and spleen disorders. Dr. Arnoletti’s clinical focus is the multi-disciplinary care of patients with GI cancers placing great emphasis on minimally invasive surgical techniques. He is Florida Hospital’s Chief of Surgical Oncology and consults with patients in his offices at the Center for Specialized Surgery next to Florida Hospital Orlando. He also serves as a Professor of Surgery at the University of Central Florida College of Medicine and Florida State University.
Dr. Arnoletti comes to Central Florida from Birmingham, Ala., where he previously served as an Associate Professor of Surgery and director of the Surgical Oncology Laboratory at the University of Alabama at Birmingham (UAB) and as Clinical Core Co-Director of the UAB Pancreatic Cancer Program. He has built a reputation for his leading research in cancer care, including groundbreaking discoveries as part of the National Cancer Institute Specialized Program of Research Excellence (SPORE), and has authored more than 50 peer-reviewed articles in medical publications. Dr. Arnoletti’s outstanding reputation and patient reviews have earned him “Best Doctor” and “Top Doctor” designations in Birmingham Magazine and Orlando Magazine, respectively.
- Colorectal Cancer Surgery
- Gastrointestinal Surgical Oncology
- Hepato-Biliary Cancer
- Liver Cancer
- Minimally-Invasive Surgery
- Pancreatic Cancer
- Soft Tissue Sarcomas
- Stomach Cancer
- Project Title: [615759-1] Cancer Biomarkers in Pancreatic Cancer Principal Investigator: Pablo Arnoletti, MD
- Project Title: [507397-2] Prospective Studies Using Peri-Ampullar and Pancreatic Tumor Tissues
- Principal Investigator: Pablo Arnoletti
- Project Title: [584951-2] Biomarker Characterization and ex vivo Treatment Sensitivity Studies in Hepatobiliary Cancer: Fresh Tissue and Blood Analyses
- Principal Investigator: Pablo Arnoletti, MD
- Project Title: [559269-1] In vivo platform for molecular assessment of new pancreatic cancer therapies
- Principal Investigator: J. Pablo Arnoletti, MD
- Anal Carcinoma, Version 2, 2012: Featured Updates to the NCCN Guidelines
- Pancreatic Adenocarcinoma, Version 2, 2012: Featured Updates to the NCCN Guidelines
- Endoscopic ultrasound evaluation in the surgical treatment of duodenal and peri-ampullary adenomas.
- Liles JS, Arnoletti JP, Kossenkov AV, Mikhaylina A, Frost AR, Kulesza P, Heslin MJ, Frolov A. Targeting ErbB3-mediated stromal-epithelial interactions in pancreatic ductal adenocarcinoma. British Journal of Cancer 105:523-33, 2011.
Best in Docs: A Journey to Inspire.
At 70, Pru Mabry, of Melbourne, was diagnosed with stage III pancreatic cancer. At the time, she was a special needs teacher with no plans to retire. “Before the cancer, I probably would have worked until I was 80.”
However, discoloration in her urine, along with a case of jaundice and unexpected weight loss, led her to seek medical testing, including a biopsy.
Her gastroenterologist... Click here to read more.